phase 3

Close up shot of the target from a dart game
Pharma

Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis

Already on a roll with Vyvgart, argenx has posted trial results that could allow for it to reach a new indication—ocular myasthenia gravis.
Kevin Dunleavy Feb 26, 2026 11:18am
bacteria and virus science on chalkboard
Favicon Fierce Biotech

US vaccine landscape ‘100%’ impacting business: Bancel

Jan 23, 2026 1:26pm
accelerated

IntraBio's Aqneursa tees up 2nd rare disease nod with ph. 3 win

Jan 21, 2026 11:48am
Close up shot of the target from a dart game

Foresee eyes rare puberty disease nod for Camcevi with trial win

Jan 2, 2026 11:03am
10 in chalk

Tenpoint preps FDA filing after scoring in presbyopia study

Jan 9, 2025 3:39pm
Graphic of a drop of blood made up of small data points and nodes

Grifols preps blood clot treatment approval push after ph. 3 win

Feb 14, 2024 9:10am